Dr. Reddy`s Laboratories Overview
Dr. Reddy`s Laboratories (RDY) has a ROE of 8.65%, above the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow8.65%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for RDY is 8.65%. That is above the Healthcare sector average of -100.59%. Investors often review this figure alongside Dr. Reddy`s Laboratories's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RDY currently prints 8.65% for ROE, while the sector average sits near -100.59%. That is roughly 108.6% above the sector mean. Large gaps often invite a closer look at Dr. Reddy`s Laboratories's growth, margins, and balance sheet.
Return on Equity shows how effectively Dr. Reddy`s Laboratories converts resources into returns. At 8.65%, RDY may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting RDY's ROE (8.65%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Dr. Reddy`s Laboratories's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
